GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » Interest Coverage

ABVC (ABVC BioPharma) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. ABVC BioPharma's Operating Income for the three months ended in Dec. 2024 was $-0.33 Mil. ABVC BioPharma's Interest Expense for the three months ended in Dec. 2024 was $0.34 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for ABVC BioPharma's Interest Coverage or its related term are showing as below:


ABVC's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 112.28
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


ABVC BioPharma Interest Coverage Historical Data

The historical data trend for ABVC BioPharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ABVC BioPharma Interest Coverage Chart

ABVC BioPharma Annual Data
Trend Sep15 Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ABVC BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.23 -

Competitive Comparison of ABVC BioPharma's Interest Coverage

For the Biotechnology subindustry, ABVC BioPharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABVC BioPharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's Interest Coverage falls into.


;
;

ABVC BioPharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ABVC BioPharma's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, ABVC BioPharma's Interest Expense was $-0.83 Mil. Its Operating Income was $-4.71 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.24 Mil.

ABVC BioPharma did not have earnings to cover the interest expense.

ABVC BioPharma's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, ABVC BioPharma's Interest Expense was $0.34 Mil. Its Operating Income was $-0.33 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


ABVC BioPharma  (NAS:ABVC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


ABVC BioPharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of ABVC BioPharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


ABVC BioPharma Business Description

Traded in Other Exchanges
N/A
Address
44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Executives
Shuling Jiang director, 10 percent owner 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng director 5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira director 4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto director 4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao director NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang director, officer: CSO and Director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang director, officer: Chairman of the Board & CBO 1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou director 13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King officer: Chief Scientific Officer 11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong officer: Chief Executive Officer 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An officer: Chief Financial Officer 32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang director 1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar director, 10 percent owner, officer: President,Secretary,Treasurer 8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz officer: CFO & Controller 2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326